Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BTK |
| Variant | mutant |
| Impact List | unknown |
| Protein Effect | unknown |
| Gene Variant Descriptions | BTK mutant indicates an unspecified mutation in the BTK gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
BTK mutant |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03331198 | Phase Ib/II | Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Active, not recruiting | USA | CAN | 0 |
| NCT04209621 | Phase II | Duvelisib + Ibrutinib | Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Terminated | USA | 0 |
| NCT04189757 | Phase II | Acalabrutinib | Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT02914327 | Phase I | Ibrutinib + SNX-5422 | Safety and Activity of SNX-5422 Plus Ibrutinib in CLL | Withdrawn | USA | 0 |
| NCT04515238 | Phase II | Bendamustine + Obinutuzumab + Venetoclax + Zanubrutinib | Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG) | Active, not recruiting | DEU | 0 |
| NCT04883749 | Phase II | Acalabrutinib | Efficacy of Acalabrutinib in Very Old or Frail Patients with Treatment-naïve or Relapsed/Refractory CLL (CLL-Frail) | Completed | DEU | AUT | 0 |